Not great to see, but I think the management is taking its medicine, and it sets them up well for FY25 to clear a lower comparables bar. They should also be helped by Medicare indexation kicking in for pathology services after a long time with no indexation.

I bought the dip, though we could still be offered better prices over the months ahead.

I see this as buying opportunity. Long term performer and dividend stalwart with a PE of 22… topped up in RL today